ArticlePloS one2026
Rigorous validation of graph-based network analysis reappraises biologically coherent ADHD-associated transcriptomic modules in peripheral blood.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGraph attention networks (GATs) are increasingly applied to transcriptomic data because they integrate gene-network structure while producing attention weights that are often interpreted as indicators of biological importance. However, whether attention-derived explanations reliably reflect biologically meaningful signals has received little systematic evaluation, particularly in the small, heterogeneous cohorts common in psychiatric transcriptomics.
methodsWe systematically re-evaluated a GAT using peripheral blood RNA-sequencing data from 76 individuals (39 ADHD, 37 controls), including 16 discordant monozygotic twin pairs. To maximize analytical rigor, we implemented a leakage-aware pipeline, incorporating twin-aware group-stratified cross-validation, fold-wise gene selection, corrected transcript-to-gene mapping, and validation through repeated cross-validation, permutation testing, three complementary feature-importance methods, orthogonal differential-expression and pathway analyses, and data-quality controls.
resultsAcross 20 repeated cross-validation splits, GAT achieved a slightly higher mean AUC than a graph convolutional network (mean AUC 0.624 vs. 0.599) and outperformed five classical machine-learning models on a prespecified split. However, GAT performance was not statistically distinguishable from a rigorously matched permutation-derived null distribution (p = 0.327), while an exploratory sample-size calculation indicated that roughly twice the current sample size would be needed to detect an effect this size at conventional power. Independent validation analyses converged on the same conclusion: attention-derived gene rankings were significantly negatively correlated with both SHAP and permutation importance, whereas differential-expression analyses---including discordant twin-pair comparisons---and pathway enrichment identified no reproducible biological signals after multiple-testing correction. Recovery of established co-expression modules and the absence of blood-cell marker differences supported pipeline validity.
conclusionsGraph-based models may show modest predictive gains, but predictive performance and biological interpretation are distinct scientific questions. Our findings demonstrate that attention-derived importance should be regarded as hypothesis-generating rather than mechanistic evidence unless independently validated, illustrating why rigorous, multi-level validation is essential before biological conclusions are drawn from graph neural networks in transcriptomic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.